Next Article in Journal
Bacterial Aspartyl-tRNA Synthetase Has Glutamyl-tRNA Synthetase Activity
Next Article in Special Issue
FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy
Previous Article in Journal
Meeting the Challenge of Eliminating Chronic Hepatitis B Infection
Previous Article in Special Issue
Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment
Review

Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine

1
Department of Clinical Pharmacy, San Cecilio University Hospital, Institute for Biomedical Research, ibs.GRANADA, 18016 Granada, Spain
2
Genomics Unit, Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (Genyo), 18016 Granada, Spain
3
English Department, Official Language School Leganes, 28915 Leganés, Madrid, Spain
*
Author to whom correspondence should be addressed.
Genes 2019, 10(4), 261; https://doi.org/10.3390/genes10040261
Received: 8 February 2019 / Revised: 25 March 2019 / Accepted: 26 March 2019 / Published: 1 April 2019
(This article belongs to the Special Issue Pharmacogenomics and Personalized Medicine)
There is a special interest in the implementation of pharmacogenetics in clinical practice, although there are some barriers that are preventing this integration. A large part of these pharmacogenetic tests are focused on drugs used in oncology and psychiatry fields and for antiviral drugs. However, the scientific evidence is also high for other drugs used in other medical areas, for example, in cardiology. In this article, we discuss the evidence and guidelines currently available on pharmacogenetics for clopidogrel, warfarin, acenocoumarol, and simvastatin and its implementation in daily clinical practice. View Full-Text
Keywords: pharmacogenetics; clopidogrel; warfarin; acenocoumarol pharmacogenetics; clopidogrel; warfarin; acenocoumarol
MDPI and ACS Style

Dávila-Fajardo, C.L.; Díaz-Villamarín, X.; Antúnez-Rodríguez, A.; Fernández-Gómez, A.E.; García-Navas, P.; Martínez-González, L.J.; Dávila-Fajardo, J.A.; Cabeza Barrera, J. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. Genes 2019, 10, 261. https://doi.org/10.3390/genes10040261

AMA Style

Dávila-Fajardo CL, Díaz-Villamarín X, Antúnez-Rodríguez A, Fernández-Gómez AE, García-Navas P, Martínez-González LJ, Dávila-Fajardo JA, Cabeza Barrera J. Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine. Genes. 2019; 10(4):261. https://doi.org/10.3390/genes10040261

Chicago/Turabian Style

Dávila-Fajardo, Cristina L., Xando Díaz-Villamarín, Alba Antúnez-Rodríguez, Ana E. Fernández-Gómez, Paloma García-Navas, Luis J. Martínez-González, José A. Dávila-Fajardo, and José Cabeza Barrera. 2019. "Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine" Genes 10, no. 4: 261. https://doi.org/10.3390/genes10040261

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop